penicillamine has been researched along with Alzheimer Disease in 11 studies
Penicillamine: 3-Mercapto-D-valine. The most characteristic degradation product of the penicillin antibiotics. It is used as an antirheumatic and as a chelating agent in Wilson's disease.
penicillamine : An alpha-amino acid having the structure of valine substituted at the beta position with a sulfanyl group.
Alzheimer Disease: A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)
| Excerpt | Relevance | Reference |
|---|---|---|
| "When compared to patients prescribed donepezil, galantamine, or memantine, individuals prescribed rivastigmine were almost twice as likely to report dysphagia as an adverse event." | 8.12 | Dysphagia Risk in Patients Prescribed Rivastigmine: A Systematic Analysis of FDA Adverse Event Reporting System. ( Bu, K; Cheng, F; Han, W; Morris, R; Patel, D; Umeukeje, G; Zhu, T, 2022) |
| "When compared to patients prescribed donepezil, galantamine, or memantine, individuals prescribed rivastigmine were almost twice as likely to report dysphagia as an adverse event." | 4.12 | Dysphagia Risk in Patients Prescribed Rivastigmine: A Systematic Analysis of FDA Adverse Event Reporting System. ( Bu, K; Cheng, F; Han, W; Morris, R; Patel, D; Umeukeje, G; Zhu, T, 2022) |
| "Some of the implications are that Alzheimer's disease and other diseases of neurodegeneration and fibrotic, inflammatory, and autoimmune diseases may be treatable by lowering the availability of free copper." | 2.44 | The risks of free copper in the body and the development of useful anticopper drugs. ( Brewer, GJ, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (9.09) | 18.2507 |
| 2000's | 7 (63.64) | 29.6817 |
| 2010's | 1 (9.09) | 24.3611 |
| 2020's | 2 (18.18) | 2.80 |
| Authors | Studies |
|---|---|
| Moret, V | 1 |
| Laras, Y | 1 |
| Pietrancosta, N | 1 |
| Garino, C | 1 |
| Quéléver, G | 1 |
| Rolland, A | 1 |
| Mallet, B | 1 |
| Norreel, JC | 1 |
| Kraus, JL | 1 |
| Bu, K | 1 |
| Patel, D | 1 |
| Morris, R | 1 |
| Han, W | 1 |
| Umeukeje, G | 1 |
| Zhu, T | 1 |
| Cheng, F | 1 |
| Cilliers, K | 1 |
| Sun, D | 1 |
| Zhang, W | 1 |
| Yu, Q | 1 |
| Chen, X | 1 |
| Xu, M | 1 |
| Zhou, Y | 1 |
| Liu, J | 1 |
| Brewer, GJ | 1 |
| Rossi, L | 2 |
| Squitti, R | 2 |
| Pasqualetti, P | 2 |
| Marchese, E | 1 |
| Cassetta, E | 2 |
| Forastiere, E | 1 |
| Rotilio, G | 1 |
| Rossini, PM | 2 |
| Finazzi-Agró, A | 2 |
| Cui, Z | 1 |
| Lockman, PR | 1 |
| Atwood, CS | 1 |
| Hsu, CH | 1 |
| Gupte, A | 1 |
| Allen, DD | 1 |
| Mumper, RJ | 1 |
| Gasparini, L | 1 |
| Ghidoni, R | 1 |
| Alberici, AC | 1 |
| Benussi, L | 1 |
| Moratto, D | 1 |
| Trabucchi, M | 1 |
| Growdon, JH | 1 |
| Nitsch, RM | 1 |
| Binetti, G | 1 |
| Fass, U | 1 |
| Panickar, K | 1 |
| Personett, D | 1 |
| Bryan, D | 1 |
| Williams, K | 1 |
| Gonzales, J | 1 |
| Sugaya, K | 1 |
| McKinney, M | 1 |
| Cherny, RA | 1 |
| Barnham, KJ | 1 |
| Lynch, T | 1 |
| Volitakis, I | 1 |
| Li, QX | 1 |
| McLean, CA | 1 |
| Multhaup, G | 1 |
| Beyreuther, K | 1 |
| Tanzi, RE | 1 |
| Masters, CL | 1 |
| Bush, AI | 1 |
| Moffa, F | 1 |
| Cortesi, M | 1 |
| Colloca, A | 1 |
2 reviews available for penicillamine and Alzheimer Disease
| Article | Year |
|---|---|
Trace element alterations in Alzheimer's disease: A review.
Topics: Alzheimer Disease; Clioquinol; Copper; Deferoxamine; Humans; Metals; Penicillamine; Siderophores; Tr | 2021 |
The risks of free copper in the body and the development of useful anticopper drugs.
Topics: Alzheimer Disease; Angiogenesis Inhibitors; Autoimmunity; Copper; Fibrosis; Hepatolenticular Degener | 2008 |
2 trials available for penicillamine and Alzheimer Disease
| Article | Year |
|---|---|
Red blood cell copper, zinc superoxide dismutase activity is higher in Alzheimer's disease and is decreased by D-penicillamine.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Chi-Square Distribution; Copper; D | 2002 |
d-penicillamine reduces serum oxidative stress in Alzheimer's disease patients.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Chelating Agents; Copper; Disease Progression; Female; H | 2002 |
7 other studies available for penicillamine and Alzheimer Disease
| Article | Year |
|---|---|
1,1'-Xylyl bis-1,4,8,11-tetraaza cyclotetradecane: a new potential copper chelator agent for neuroprotection in Alzheimer's disease. Its comparative effects with clioquinol on rat brain copper distribution.
Topics: Alzheimer Disease; Animals; Chelating Agents; Clioquinol; Copper; Heterocyclic Compounds, 1-Ring; Mo | 2006 |
Dysphagia Risk in Patients Prescribed Rivastigmine: A Systematic Analysis of FDA Adverse Event Reporting System.
Topics: Acetylcholinesterase; Alzheimer Disease; Butyrylcholinesterase; Cholinesterase Inhibitors; Clozapine | 2022 |
Chiral penicillamine-modified selenium nanoparticles enantioselectively inhibit metal-induced amyloid β aggregation for treating Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Cell Survival; Me | 2017 |
Novel D-penicillamine carrying nanoparticles for metal chelation therapy in Alzheimer's and other CNS diseases.
Topics: Alzheimer Disease; Central Nervous System Diseases; Chelating Agents; Copper; Drug Carriers; Drug St | 2005 |
Modulation of presenilin-1 processing by nitric oxide during apoptosis induced by serum withdrawal and glucose deprivation.
Topics: Alzheimer Disease; Apoptosis; Benzoates; Culture Media, Serum-Free; Cytochrome c Group; Deoxyglucose | 1999 |
Differential vulnerability of primary cultured cholinergic neurons to nitric oxide excess.
Topics: Acetylcholine; Alzheimer Disease; Animals; Brain Stem; Cell Survival; Cells, Cultured; Choline O-Ace | 2000 |
Chelation and intercalation: complementary properties in a compound for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; Chelating Agents; Copper; Humans; Mice; Mi | 2000 |